Recently QVQ has decided to invest in Orthros TR, a company that will develop bi-functional VHH to cure Osteoarthritis.
This investment follows on the agreement between Orthros TR and QVQ in which Orthros has obtained a License Agreement on the commercialization of QVQ molecules for therapeutic purposes in the field of tissue repair, particularly Osteoarthritis. QVQ will in return receive royalty payments on the sales of these molecules.
Furthermore, this investment ensures that QVQ can provide its customers with services related to the GMP production of VHH. Thereby QVQ has the unique ability to provide all services from the immunization of llamas, selection of the best binders, optimization and humanization, large scale production in yeast until the clinic productions under GMP conditions with its close partners.